AnaptysBio financials
$50.37−0.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 | Q2 '23 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.6M | $108.2M | $76.3M | $22.3M | $27.8M | $43.1M | $30.0M | $11.0M | $7.2M | $9.0M | $3.3M | $3.5M |
| Gross profit | $25.6M | $108.2M | $76.3M | $22.3M | $27.8M | $43.1M | $30.0M | $11.0M | $7.2M | $9.0M | $3.3M | $3.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$34.6M | $66.9M | $34.7M | -$26.2M | -$27.5M | -$9.7M | -$22.8M | -$40.3M | -$42.2M | -$42.1M | -$37.7M | -$40.1M |
| Net income | -$52.9M | $49.6M | $15.1M | -$38.6M | -$39.3M | -$21.8M | -$32.9M | -$46.7M | -$43.9M | -$42.2M | -$37.3M | -$39.8M |
| Net margin | −206.9% | 45.8% | 19.8% | −173.5% | −141.6% | −50.5% | −109.4% | −425.3% | −612.0% | −468.8% | −1124.4% | −1151.6% |
| Diluted EPS | $-1.84 | $1.87 | $0.52 | $-1.34 | $-1.28 | $-0.71 | $-1.14 | $-1.71 | $-1.64 | $-1.59 | $-1.41 | $-1.50 |
| EBITDA | -$34.5M | $67.0M | $34.8M | -$26.0M | -$27.4M | -$9.5M | -$22.6M | -$40.2M | -$42.0M | -$34.6M | -$37.6M | -$40.0M |
| Operating cash flow | -$25.9M | $98.0M | -$27.4M | -$40.2M | -$10.7M | -$66.7M | -$10.1M | -$21.3M | -$37.3M | -$34.3M | -$36.5M | -$25.4M |
| Free cash flow | -$25.9M | $98.0M | -$27.4M | -$40.3M | -$10.7M | -$66.9M | -$10.1M | -$21.4M | -$37.3M | -$34.6M | -$36.6M | -$25.6M |
| Diluted shares | 28.7M | 26.6M | 29.0M | 28.8M | 30.6M | 30.5M | 28.9M | 27.4M | 26.8M | 26.6M | 26.5M | 26.6M |
Balance sheet
| Period end | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $248.5M | $238.2M | $109.8M | $44.3M | $98.6M | $123.1M |
| Short-term investments | $38.0M | $73.4M | $139.1M | $221.4M | $241.3M | $262.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $329.7M | $364.4M | $353.1M | $335.3M | $422.1M | $483.8M |
| Total liabilities | $316.9M | $327.2M | $382.5M | $380.0M | $388.0M | $413.0M |
| Shareholders' equity | $12.7M | $37.2M | -$29.4M | -$44.7M | $34.0M | $70.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology